Eye drops for patients with Presbyopia
How do presbyopia-correcting drops work?
Presbyopia occurs when the clear lens of the eye stiffens over time and loses flexibility. This reduces the ability of the lens to focus incoming light from near objects onto the retina. Signs of presbyopia include difficulty reading a menu in dim restaurant lighting or fine print that appears blurry on a smartphone. Topical eyedrop treatments, known as “miotic drops”, work by making the pupil contract to create a ‘pinhole effect.’ This increases the eye’s depth of focus and helps you see with greater sharpness.
Who might benefit from presbyopia eye drops? Not everyone is a candidate for drop therapy. Presbyopia drops work best in people with mild to moderate presbyopia. If you have never worn glasses before or use single vision glasses and want to avoid a bifocal or multifocal lens, you have a higher likelihood of success with drop therapy. Today, three different prescription eyedrops have been FDA-approved as treatments for presbyopia:
Source: American Academy of Ophthalmology. Published Oct. 28, 2025
Presbyopia occurs when the clear lens of the eye stiffens over time and loses flexibility. This reduces the ability of the lens to focus incoming light from near objects onto the retina. Signs of presbyopia include difficulty reading a menu in dim restaurant lighting or fine print that appears blurry on a smartphone. Topical eyedrop treatments, known as “miotic drops”, work by making the pupil contract to create a ‘pinhole effect.’ This increases the eye’s depth of focus and helps you see with greater sharpness.
Who might benefit from presbyopia eye drops? Not everyone is a candidate for drop therapy. Presbyopia drops work best in people with mild to moderate presbyopia. If you have never worn glasses before or use single vision glasses and want to avoid a bifocal or multifocal lens, you have a higher likelihood of success with drop therapy. Today, three different prescription eyedrops have been FDA-approved as treatments for presbyopia:
- Vuity (pilocarpine hydrochloride ophthalmic solution 1.25%), introduced by AbbVie in 2021
- Qlosi (pilocarpine ophthalmic solution 0.4%), introduced by Orasis Pharmaceuticals in 2025
- VIZZ (aceclidine hydrochloride 1.75%), introduced by LENZ Therapeutics in 2025
Source: American Academy of Ophthalmology. Published Oct. 28, 2025